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Abstract
Platelets are well-known for their critical role in hemostasis, i.e. the prevention of blood loss at
sites of mechanical vessel injury. Inappropriate platelet activation and adhesion, however, can lead
to thrombotic complications, such as myocardial infarction and stroke. To fulfill its role in
hemostasis, the platelet is equipped with various G protein-coupled receptors (GPCRs) that
mediate the response to soluble agonists such as thrombin, ADP, and thromboxane A2. In addition
to GPCRs, platelets express three glycoproteins (GP) that belong to the family of immunoreceptor
tyrosine-based activation motif (ITAM) receptors: Fc receptor (FcR) γ chain, which is non-
covalently associated with the GPVI collagen receptor, C-type lectin 2 (CLEC2), the receptor for
podoplanin, and FcγRIIA, a low-affinity receptor for immune complexes. While both genetic and
chemical approaches have documented a critical role for platelet GPCRs in hemostasis, the
contribution of ITAM receptors to this process is less defined. Studies performed over the last
decade, however, have identified new roles for platelet ITAM signaling in vascular integrity in
utero and at sites of inflammation. The purpose of this review is to summarize recent findings on
how platelet ITAM signaling controls vascular integrity, both in the presence and absence of
mechanical injury.
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1. Platelet ITAM signaling in hemostasis and thrombosis
A monolayer of endothelial cells separates the lumen of blood vessels from the extracellular
matrix (ECM). Upon mechanical disruption of this monolayer, blood gets into contact with
the various components of the ECM 1. Proteins soluble in blood, such as von Willebrand
factor (VWF) and clotting factors, are rapidly deposited in the ECM. As a consequence,
platelets are recruited to the site of injury, followed by their activation and firm adhesion.
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Transient adhesion of platelets (tethering) depends largely on VWF and its receptor, the
GPIb-V-IX complex. Firm adhesion requires the inside-out activation of integrin receptors
such as αIIbβ3, α2β1, and α6β1, followed by interaction with their respective ligands in the
ECM (see below). Critical to the activation process is signaling provided by GPCRs, agonist
receptors triggered by soluble mediators such as thrombin (a main protease of the
coagulation cascade) or thromboxane (Tx)A2 and ADP (agonists released by activated
platelets and red blood cells 2). The molecular mechanisms underlying the various stages of
thrombus formation at sites of vascular injury have been reviewed extensively 3, 4 and will
thus not be discussed in detail. Instead, we will summarize important findings on the
contribution of ITAM signaling to platelet adhesion at sites of vascular injury.
1.1 GPVI
Collagen has long been known to be a potent activator of platelets as well as a strong
adhesive ligand by which activated platelets may adhere to an injured vessel wall in the face
of arterial shear forces. These two platelet responses to collagen are mediated by structurally
and functionally distinct receptors, GPVI and integrin α2β15, 6. GPVI is an Ig domain-
containing transmembrane protein that is structurally homologous to immune-type receptors.
Its short cytoplasmic tail does not have signaling activity but facilitates the non-covalent
association with the ITAM-containing FcRγ chain. Collagen is an abundant protein in the
body that is secreted into the ECM predominantly by fibroblasts 7. The basement membrane
underneath the EC layer contains mostly type IV collagen. Unlike the fibrillar collagens type
I, III, and V, which are found in deeper layers of the ECM, type IV collagen forms 2-
dimensional networks. Compared to fibrillar collagens, type IV collagen shows lower
platelet activating activity8. However, collagen type IV is important for GPVI-dependent
platelet activation at sites of superficial vascular injury 9. Interestingly, GPVI is less critical
for thrombus formation at sites of more severe injury as documented in various (mouse)
models of thrombotic disease 9. Consistent with this finding, the bleeding times in
humans 10 and mice 11 with defective GPVI function are only minimally prolonged. The
likely explanation for this unexpected result is that thrombin, produced via the tissue factor-
dependent coagulation pathway, provides a strong enough stimulus for platelet activation in
the absence of GPVI engagement. It is important to note, however, that the reverse is not
true. Deficiency in PAR4, the main GPCR expressed on mouse platelets, cannot be
compensated for by signaling via GPVI 12, 13. The hemITAM receptor CLEC2 may also
contribute to platelet activation and thrombus formation in the deeper layers of the ECM
(see below). In addition to collagen, GPVI also binds laminins, heterotrimeric glycoproteins
consisting of α, β, and γ chains 7. Laminins, in particular α4 and α5 laminins, are
predominantly found in the basement membrane. GPVI has an ~10-fold lower affinity for
laminin when compared to collagen 14, a fact that may explain why binding of platelets to
laminin via integrin α6β1 is a prerequisite for the GPVI-laminin interaction. Elegant studies
by Mangin and colleagues recently confirmed the critical role of α6β1 for platelet adhesion
at sites of vascular injury 15. Using α6-deficient mice, the authors demonstrated that α6β1 is
critical for platelet adhesion to α4 and α5 laminins in vitro and for normal thrombus
formation in vivo. In contrast, platelets deficient in GPVI were normal in their ability to
adhere to laminin in vitro, while they showed a minor activation defect specifically to α5
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laminins. However, binding of GPVI to laminin may play a bigger role in vivo, where
laminin is found together with type IV collagen in the basement membrane.
1.2 CLEC2
CLEC2 was identified in platelets as a receptor for the snake venom toxin rhodocytin and
for the transmembrane glycoprotein Podoplanin (PDPN; aka T1alpha, gp38 and Aggrus) 16.
CLEC2 is highly expressed on platelets but it is also found at a lower level on immune cells
(dendritic cells, monocyte/macrophages, neutrophils) 17, 18. The intracellular domain of
CLEC2 contains a single YxxL motif (known as a hemiITAM motif) 6. Clustering of
CLEC2 by PDPN triggers a powerful platelet signaling response similar to that established
for GPVI and FcγRIIA. Podoplanin is a heavily glycosylated type 1 transmembrane protein
expressed in a variety of tissues: kidney podocytes, type-1 lung alveolar cells, lymphatic
endothelial cells, the nervous sytem and metastatic tumour cells 19. The importance of
CLEC2 in hemostasis remains controversial. Various studies using mice deficient in CLEC2
showed normal hemostasis in these mice 20, 21, 22. One study in mice depleted of CLEC2 by
infusion of a monoclonal antibody to the receptor observed a significant prolongation of the
tail bleeding time 23, while a similar treatment did not affect hemostasis in a different
study 22. The study by Bender et al. further investigated the effect of combined deficiency in
CLEC2 and GPVI on hemostasis 22. While antibody-induced depletion of both receptors
from circulating platelets led to a marked prolongation of the tail bleeding time in mice, the
defect in hemostasis was much more subtle in animals with a genetic deficiency in both
receptors. It is important to remember that both approaches to eliminate CLEC2 from
platelets have limitations. Antibody-induced depletion of CLEC2 may affect platelet
activation in ways that are independent of CLEC2. Such off-target effects were shown for
antibodies to GPVI, which when injected into mice transiently affect thrombin activation of
platelets 24. On the other hand, genetic deletion of CLEC2 affects the integrity of blood
vessels and allows blood to enter the lymphatic circulation (see below), alterations that
could certainly affect the bleeding time in mice. Assuming there is a role for CLEC2 in
hemostasis, the obvious question is how platelet CLEC2 signaling is initiated at the site of
vascular injury. Expression of podoplanin, the only known endogenous ligand of CLEC2,
has not been documented in cells of the vascular wall 25. Blood cells, including platelets,
also lack podoplanin. Thus, a critical role for CLEC2 in hemostasis would suggest the
existence of a CLEC2 ligand other than podoplanin, or a homotypic interaction between
CLEC2 receptors as recently suggested 26. Further studies are needed to clarify the
underlying mechanism.
1.3 FcγRIIA
Another ITAM receptor expressed on human platelets is a low affinity member of the Fcγ
(IgG binding) family of Fc receptors, FcγRIIA (CD32A). Mice lack the genetic equivalent
of human FcγRIIA, but transgenic mice expressing the human receptor 27 have been used to
study its biology in vivo. FcγRIIA allows platelets to play a role in innate immunity by
binding to and becoming activated by pathogens opsinized with antibody, thus speeding
their clearance 28, 29, 30, 31. Platelet activation through the platelet Fcγ receptor, FcγRIIA,
also plays a critical role in the pathogenesis of various immune-mediated thrombocytopenia
and thrombosis (ITT) syndromes, including heparin-induced thrombocytopenia and
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thrombosis (HIT) 32–34, bacterial sepsis–associated thrombocytopenia and disseminated
intravascular coagulation (DIC) 28, 29 and the varied thrombotic manifestations in the
antiphospholipid syndromes (APLSS) 35.
At sites of vascular injury, FcγRIIA supports thrombus formation via its contribution to
integrin outside-in signaling. As shown by Newman and colleagues 36, 37, increased integrin
signaling in platelets expressing human FcγRIIA leads to significantly better spreading,
aggregation and adhesion to collagen under flow in vitro. Consistently, thrombus formation
was significantly increased in mice expressing human FcγRIIA when compared to WT
controls.
1.4 Signaling downstream of (hem)ITAM receptors
Critical to the signaling activity of (hem)ITAM receptors are the cytosolic YXXL motifs
which when phosphorylated serve as a docking site for SH2 domain containing signaling
molecules 38, 39. Typical ITAM receptors such as GPVI/Fcγ chain and FcγRIIA contain
two cytosolic YXXL motifs, separated by 6–12 residues, which facilitate the binding of the
two SH2 domains of the non-receptor tyrosine kinase Syk 40, 6. CLEC2 contains only one
such motif in its cytoplasmic tail. To enable Syk binding to two phosphorylated hemITAM
motifs, CLEC2 exists as a homodimer on the cell surface 41. The binding and activation of
Syk is a critical event in the formation of a signalosome consisting of various adapter and
effector proteins. Central to the formation of the signalosome is linker for activation of T
cells (LAT), which is localized to lipid rafts 42, 43. Phosphorylated LAT recruits the adapter
proteins Grb2, Gads, and SLP-7644. Both LAT and SLP-76 45 contribute to the binding of
phospholipase Cγ2 (PLCγ2), the enzyme required for the generation of the second
messengers calcium (Ca2+) and diacylglycerol (DAG). Genetic deficiency in mice of any of
the proteins mentioned above leads to severely impaired ITAM signaling in platelets. Other
adapters and effectors that associate with the ITAM signalosome, such as Signal Transducer
and Activator of Transcription 3 (STAT3) 46, the small GTPase Rac1 47, 48, 49 and its
exchange factors Vav1 and Vav3 50–52, the tyrosine kinases Btk 53 and Tec 54, or various
PI3 kinase isoforms 55 also contribute to effective signaling. Downstream of PLCγ2, the
small GTPase Rap1 orchestrates various cellular responses, including integrin
activation 56, 57, 58 TxA2 formation 59, and granule release 49, 60. The guanine nucleotide
exchange factor, CalDAG-GEFI (RasGRP2), senses increased levels of cytosolic Ca2+ and
facilitates the rapid but reversible activation of Rap1. DAG leads to delayed Rap1 activation
via stimulation of protein kinase C-dependent granule release and feedback activation
through the Gi-coupled receptor for ADP, P2Y12. Platelet ITAM signaling strongly depends
on the Ca2+/CalDAG-GEFI/Rap1 pathway as deficiency in CalDAG-GEFI protects mice
from collagen- and immune complex-induced thrombosis 57, 61. It is important to remember,
however, that signaling molecules downstream of PLCγ2 such as CalDAG-GEFI and PKC
are also critical for PLCβ-dependent GPCR signaling in platelets. Thus, we focused on
literature that evaluated hemostasis and thrombosis in humans and animals with defects in
signaling proteins upstream of PLCγ2 (table 1). Interestingly, genetic deletion or inhibition
of Syk, a molecule central to signaling by all ITAM receptors on platelets, protects from
thrombosis but does not affect hemostasis in mice 62, 63. In contrast, mice deficient in
PLCγ2 are protected from experimental thrombosis but also exhibit a marked defect in
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hemostasis 64, 65, 66. A comprehensive analysis of the hemostasis and thrombosis
phenotypes in mice with defects in signaling molecules upstream of PLCγ2 is shown in
Table 1. This unexpected discrepancy in results may be explained by different experimental
approaches used in the respective labs or it may reflect the well-documented role of PLCγ2
signaling downstream of ligand binding to GPIbα 66, 67, 68. In summary, these studies
document that ITAM signaling plays a minor role for platelet adhesion at sites of vascular
injury when compared to signaling via platelet GPCRs.
2. Platelet ITAM signaling and blood-lymphatic separation
2.1. Lymphatics in the cardiovascular system
Cardiovascular function requires distinct blood and lymphatic vascular networks to circulate
blood and drain interstitial fluid from the periphery 69. The partitioning of these two
vascular compartments represents a fundamental adaptation underlying the physiology of
mammals and related vertebrates; however, our understanding of the biological processes
that give rise to two distinct networks remains incomplete. The lymphatic system performs
additional functions that include dietary fat absorption, where it transports chylomicrons
from the small intestine to the blood, and adaptive immune responses, where it transports
antigens and antigen presenting cells to lymph nodes, connects lymph nodes together, and
returns lymphocytes to the blood. Lymphatics form an extensive vascular network that
originates during embryonic development from a subset of venous endothelial cells in both
the cardinal vein and intersomitic vessels that acquire lymphatic identity. Starting at E9.75
in mice, induction of the transcription factor PROX1 in these venous endothelial cells
activates lymphatic identity and these newly specified LECs bud out of the cardinal vein and
intersomitic vessels with the help of vascular endothelial growth factor-C (VEGF-C) to form
the primary lymph sacs, early structures that give rise to the entire lymphatic network 70, 71.
The structure and function of the lymphatic system differ significantly from that of the blood
vascular system. The blood vascular system propels blood at high pressures generated by
mechanical pumping of the heart in order to circulate blood in a closed loop through
pulmonary and systemic vessels. In contrast, lymph fluid is acquired from tissues through a
permeable vascular network in which lymph flow is maintained by the contraction of
collecting vessel walls, external compression, and valves. Blind ended lymphatic capillaries
with loose endothelial junctions absorb interstitial fluid and coalesce into larger collecting
vessels that then drain lymph into lymphatic ducts where protein-rich lymph fluid and
immune cells are returned to venous blood. A series of intraluminal valves divide lymphatic
vessels into functional units called lymphangions that promote forward lymph flow. In
addition, a bicuspid lympho-venous (LV) valve is present at the site of connection where
lymph drains into blood 72. The LV valves are thought to prevent blood from entering the
low pressure lymphatic system, and in humans these valves are found at the right lymphatic
duct-subclavian vein junction and the thoracic duct-subclavian vein junction.
2.2. Blood-lymphatic separation during embryonic development
Beginning almost 20 years ago, genetic studies in mice have revealed an unexpected role for
ITAM signaling during embryonic vascular development. Mice lacking the essential ITAM
signaling effectors Syk, SLP-76, or PLCα2 73, 74, 75, 76, 77 display blood-filled lymphatic
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vessels during embryonic stages and die postnatally due to impaired lymphatic function.
Tissue-specific deletion in the megakaryocyte lineage revealed that ITAM signaling in the
platelet mediates blood-lymphatic separation, with upstream components identified through
deletion of the platelet CLEC2 receptor and its ligand PDPN expressed on lymphatic
endothelial cells (LECs). Mice deficient in CLEC2 or PDPN exhibit blood-filled lymphatics
during fetal life and die shortly after birth like mice lacking Syk or SLP-76. While these
phenotypes all arise due to loss of platelet activation by lymphatic endothelial cells, it has
been unclear precisely how activated platelets affect lymphatic development in embryos.
Some studies have used in vitro approaches to suggest that activated platelets may release
granule contents that regulate lymphatic endothelial cell growth and that this is therefore an
angiogenic role for platelets 76, 78. However, we have recently demonstrated that the entry of
blood into the developing lymphatic network in late gestation embryos is through the
lympho-venous junction and that the role of platelets is to mediate an unexpected form of
inter-vascular hemostasis that supports the lympho-venous valve and prevents blood from
entering the thoracic duct 79. An important outstanding question is whether platelet function
at the lympho-venous junction or valve can explain the early blood-lymphatic mixing
observed in animals lacking platelets or PDPN-CLEC2 signaling to activate them. Deficient
embryos exhibit blood-filled lymph sacs as early as E11.5, a timepoint prior to when the
lympho-venous junction has been demonstrated to arise during lymphatic
development 80, 81. Thus it is possible that platelet CLEC2 signaling mediates inter-vascular
hemostasis in a distinct manner at early timepoints in lymphatic growth. While additional
studies are needed to address this developmental role, it is clear that the role of platelets in
this context is to perform a unique form of hemostasis and not to regulate
lymphangiogenesis.
2.3. Blood-lymphatic separation in the adult
Lethally irradiated mature mice transplanted with bone marrow deficient in CLEC2 78,
Syk 74 or SLP-76 80 develop blood-filled lymphatic vessels and die due to lymphatic
dysfunction, revealing a lifelong requirement for platelet ITAM signaling to maintain blood-
lymphatic separation. This role is also supported by inducible postnatal deletion of the O-
glycan synthase enzyme required for PDPN expression on LECs, which also produces the
blood-filled lymphatic phenotype 80, 82, 74. Platelets and LECs would not be predicted to
interact; however, the genetic experiments described above identify a critical interaction that
begins in the embryo and continues throughout life where platelets in circulating blood come
into contact with LECs to initiate platelet ITAM signaling and regulate blood-lymphatic
separation. The site where platelet CLEC2 signaling mediates blood-lymphatic separation
was recently determined by examining induced CLEC2-deficiency states in both neonatal
and mature animals 79. These studies reveal that mice lacking this signaling pathway
develop blood-filled lymphatic vessels through retrograde filling of the lymphatic network
with blood despite the presence of LV and lymphatic valves, and also identify the terminal
thoracic duct as the location where blood first enters the lymphatic vascular system
following loss of CLEC2. The LV valve has been thought to function alone in preventing
the back-flow of blood into the LV junction; however, these data suggest that an additional
platelet-dependent mechanism has escaped notice. To search for platelets at the terminal
thoracic duct, the LV junction was examined and fibrin-containing platelet thrombi were
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observed within the lymphatic vascular environment of this site (approximately 25%) in
wild-type but not CLEC2-deficient mice 79. To study the relationship between valves and
platelets at the LV junction, mice heterozygous for Prospero Homeobox Protein 1 (Prox1) or
mice lacking the Integrin α9 subunit (Itga9) were analyzed. Recent studies demonstrated
that Prox1+/− embryos exhibit lympho-venous valve defects, while Itgα9−/− embryos are
characterized by severe lymphatic valve developmental defects 83, 84, 85. These mice were
found to have an augmented frequency of LV thrombi (approx. 100%) and clots that extend
deeper within the thoracic duct than those observed in wild-type controls, suggesting that
platelets can compensate for impaired valve function 79. To stress the LV junction by
disabling platelet-mediated hemostasis, Itgb3−/− mice lacking integrin-mediated platelet
aggregation 86 were examined. These animals still form clots within the lymphatic vascular
environment yet have marked filling of the thoracic duct with blood, suggesting that
integrin-mediated platelet aggregation through αIIbβ3 is not needed for thrombus formation
in the lymphatic system yet is essential in preventing LV backflow. Together, these data
support a hemostatic mechanism of platelet function at the LV junction that maintains
blood-lymphatic separation throughout life. Unlike canonical hemostasis which limits
hemorrhage from damaged vessels, LV hemostasis operates within an uninjured
intravascular environment under low flow, low shear conditions; therefore, the contribution
of coagulation and platelet degranulation may differ from arterial or venous thrombosis.
Preliminary studies of LV hemostasis have identified a divergent role for integrin-mediated
platelet aggregation compared to arterial hemostasis where αIIbβ3 is not required for
thrombus growth but does contribute to thrombus stability in the prevention of LV
backflow.
These studies highlight an unexpected platelet-dependent hemostatic response that functions
alongside the lympho-venous valve to maintain the lymphatic system. The activation of
platelet CLEC2 receptors by lymphatic endothelial Podoplanin is first observed during
lymphatic development where it prevents blood from entering the immature system at a time
when valves are not yet formed. However, genetic and pharmacologic studies demonstrate
that the requirement for this hemostatic pathway extends throughout life, including in
mature animals in which the lympho-venous valves are fully functional. The basis for this
requirement is not yet established, but it is likely that this hemostatic mechanism is
necessary to prevent pressure gradients from driving venous blood into lymphatic vessels.
Compared to central venous pressure (5–10 mm Hg) the lymphatic pressure is low (1–2 mm
Hg). Changes in body position, fluid status or disease states such as congestive heart failure
(CHF) can further increase this pressure gradient and thus lead to backflow of blood into
lymphatic vessels. Importantly, LV valve insufficiency and reflux of blood into the thoracic
duct was recently described for patients with congestive heart failure 87. The identification
of this platelet-dependent “safety mechanism” may have clinical implications. First,
application of antiplatelet therapies to CHF patients in order to reduce the risk of myocardial
infarction and stroke may have detrimental effects on lymphatic function. Since these
patients have chronically elevated pulmonary venous pressures it is likely that lymphatic
drainage in the lung plays an important role in preventing pulmonary edema. Thus anti-
platelet therapies may protect against arterial thrombosis at the expense of lympho-venous
hemostasis and worsen CHF symptoms. Second, new drugs targeting the Syk kinase that are
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intended to treat chronic inflammatory conditions such rheumatoid arthritis, may impair
lymphatic function. The fact that these patients are expected to take anti-Syk agents for
extended periods of time raises this risk. Our ability to predict the impact of anti-platelet and
anti-Syk agents is limited at this time since this pathway has been explored almost
exclusively in mouse models. Extending these studies to patients and clinically relevant
scenarios will provide needed insight into whether and how impairment of this hemostatic
pathway affects human health and disease.
3. Platelet ITAM signaling and vascular integrity in inflammation
3.1 GPVI, atherosclerosis and enhanced vascular permeability
In addition to hemostasis and thrombosis, platelets are important modulators of
inflammatory reactions. Their role in inflammation is partially explained by their ability to
interact and communicate with leukocytes and vascular cells. These interactions are
mediated by various receptor-ligand pairs, including P-selectin – PSGL-1, GPIbα - Mac1,
CD40L -CD40, and αIIbβ3 - ICAM1 88, 89. Platelets also deposit chemokines on activated
endothelium, thereby enhancing leukocyte recruitment and promoting the progression and
propagation of chronic inflammation 90. GPVI is also critically involved in platelet adhesion
to activated endothelium. Endothelial dysfunction is considered to be a predictive sign of
atherosclerosis in patients and correlates with the progression of the disease 91. GPVI can
interact with the activated atherosclerotic endothelium in the absence of plaque rupture.
Intravital microscopy studies demonstrated that administration of soluble GPVI-Fc and anti-
GPVI (JAQ1) antibody inhibited platelet adhesion to the activated endothelium in ApoE−/−
mice 92, 93. As a consequence of this inhibition, endothelial function was improved in
atherosclerotic rabbits 93. The role of GPVI in the absence of plaque rupture in
atheroprogression is unlikely to be attributed to the interaction with collagen/laminin but
was suggested to occur through fibronectin which is secreted by activated platelets or
endothelial cells at vascular lesions 93. Similarly, in an experimental animal model of
myocardial infarction, recombinant GPVI-Fc molecules bound to activated endothelium via
vitronectin and prevented platelet/endothelial interaction thereby reducing infarct size and
preserving cardiac function 94.
Platelet ITAM signaling is also critical in inflammatory arthritis. While it was long
recognized that platelets from arthritis patients are hyper-responsive 95, it was not clear
whether platelets contribute to the progression of the disease. Studies in a mouse model of
rheumatoid arthritis, done by Boilard and colleagues, demonstrated such a causal
relationship, as mice depleted of all circulating platelets were protected from joint
inflammation 96. Interestingly, mice lacking GPVI were also protected from experimental
arthritis, suggesting that platelet ITAM signaling is critical for disease progression.
Additional work proposed the following underlying mechanisms: exposure of platelets to
collagen and laminin at sites of inflammation leads to the production of IL-1-rich,
proinflammatory microparticles (MPs) 96, platelet fragments that are small enough to diffuse
into the synovial fluid. Alternatively, platelet MPs may be transported into the joint by
inflammatory cells. Furthermore, activated platelets may actively weaken the endothelial
barrier at sites of inflammation, a process dependent on the release of serotonin from their
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dense granules 97, 98. Consistent with these findings, GPVI is important for platelet and
leukocyte recruitment to the inflamed capillaries in experimental glomerulonephritis 99.
Taken together, these studies suggest that GPVI is an attractive therapeutic target in
inflammatory diseases beyond hemostasis and thrombosis. To date, the contribution of
platelet CLEC2 and/or FcγRIIA to the pathogenesis of these diseases has not been
evaluated. Confirmatory studies in mice defective in signaling molecules downstream of
GPVI are also missing. Genetic targeting or inhibition in platelets of ITAM signaling
molecules like Syk, however, is difficult as they are also critical for proper immune cell
function. Furthermore, even platelet-specific targeting such as achieved in megakaryocyte/
platelet-specific conditional knockout mice is complicated by the marked defects in vascular
development documented for these animals (see above).
3.2 Platelets and maintenance of vascular integrity in inflammation
Platelets have long been recognized to support the integrity of the vasculature 100. Structural
endothelial abnormalities such as thinning, fenestration and increased permeability have
been shown for severely thrombocytopenic humans as well as animals depleted of virtually
all circulating platelets 101, 102. Importantly, however, thrombocytopenia is often not
associated with hemorrhage, suggesting that an additional trigger such as inflammation is
required for bleeding to occur. This multi-hit concept was confirmed in elegant studies by
Wagner and colleagues 103, who showed that acute severe thrombocytopenia in mice does
not lead to hemorrhage unless these animals are challenged by inflammation. These studies
also showed (a) that thrombocytopenia resulted in hemorrhage only at the site of
inflammation, and (b) that important platelet adhesion receptors such as GPIb-V-IX and
αIIbβ3 integrin were not required for this platelet function. Thus, the contribution of
platelets to the maintenance of vascular integrity in inflammation does not depend on the
platelet’s ability to form a hemostatic plug. At this point, very little is known about how
platelets protect the inflamed vasculature. Vasoactive factors released from activated
platelets may prevent hemorrhage by strengthening EC barrier function or by dampening the
inflammatory response 104. Numerous candidate factors, including ADP released from dense
granules 105, serpins 106,107 and metalloproteinase inhibitors 108 released from alpha
granules, reactive oxygen scavengers 109, TREM-like transcript (TLT)-1 proteolytically
shed from the platelets surface 110, 111 and the vasoactive lipid sphingosine-1 phosphate
(S1P) 112 have been identified. The extent to which these factors contribute to inflammatory
hemostasis, however, is not well-defined.
In addition to our lack of understanding with regard to the platelet protective activity, very
little is known about what triggers platelet activation at sites of inflammation and what
signaling response is required. Addressing these questions requires mice with platelet-
specific signaling defects, as the pathways regulating cellular activation are very similar
between platelets, inflammatory and vascular cells. This can be achieved by conditional
deletion of genes in the megakaryocyte lineage, an approach that depends on the availability
of mice with loxP-flanked genes that can be crossed to mice expressing Cre recombinase
under the PF4 promoter 113. As an alternative approach, we recently described a method for
the adoptive transfer of platelets into thrombocytopenic mice. In this approach
thrombocytopenia is induced in transgenic mice with antibodies that recognize hIL4R, a
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heterologous antigen expressed on circulating platelets in these animals 114, 115. These mice
are then transfused with genetically or chemically inhibited platelets, which are not
destroyed by the circulating anti hIL4R antibodies. The main characteristics of this novel
tool are: (1) a fast and reliable method to generate mice with platelet-specific signaling
defects, (2) the ability to combine genetic and pharmacologic approaches to loss of function
studies, and (3) an increased sensitivity for platelet defects due to the ability to establish a
lower peripheral platelet count in experimental animals. It is also important to remember
that deletion of genes in megakaryocytes/platelets only can lead to marked vascular changes
(see above). This limitation is not relevant for the adoptive transfer system. Using this
approach, we identified a critical role for GPVI, CLEC2, and the downstream adapter
protein SLP-76 in the maintenance of vascular integrity at sites of immune complex-induced
inflammation in the skin as well as LPS-induced inflammation in the lung 115. Surprisingly,
our studies further demonstrated that platelet GPCR signaling is not required for the
maintenance of vascular integrity in inflammation. Unlike platelets lacking functional
CLEC2 and/or GPVI, platelets defective in signaling via the major GPCRs responding to
thrombin, ADP and TxA2 were fully capable of supporting vascular integrity at sites of
inflammation.
Together, these findings confirm the notion that hemostasis at sites of inflammation requires
a platelet response(s) different to that important at sites of vascular injury (see Figure 1).
Various questions arise from these unexpected findings. For example, while the main
ligands for GPVI, collagen and laminin, are highly expressed in the vessel wall, it is not so
clear what triggers the activation of CLEC2 at sites of inflammation. Some organs that are
particularly vulnerable to hemorrhage such as the lung, the brain and the kidney contain cell
types that express high levels of PDPN 19. Other tissues, however, such as the skin do not
contain PDPN-positive cells. One possibility is that PDPN is “delivered” to the
extravascular space by infiltrating PDPN-positive macrophages 116. Alternatively, a hitherto
unrecognized ligand other than PDPN may trigger platelet CLEC2 signaling in these
situations. Conditional deletion of PDPN in various tissues will be required to clarify the
underlying mechanism. A second important question to be answered is why this novel form
of hemostasis depends so strongly on signaling via the ITAM but not the GPCR pathway. It
is difficult to imagine that this pathway selectivity simply reflects the availability of agonists
at sites of inflammation. Weakening of EC barrier function leads to plasma leakage into the
inflamed tissue, followed by the activation of coagulation and the generation of
thrombin 117. Furthermore, platelet activation via ITAM receptors and/or PAR4 leads to the
release of the second wave mediators ADP and TxA2. Thus, it appears more likely that
ITAM receptors trigger a unique platelet response, which is crucial in the setting of
inflammation. For example, there is increasing evidence that individual platelet agonist
receptors can trigger very distinct granule release reactions, although so far these studies
have been focused on platelets activated via GPCRs 118. Better established is the critical role
for ITAM signaling in platelet microparticle release and surface phosphatidylserine
exposure 119, 120 as well as shedding of surface receptors 121. Both microparticles and
soluble glycoproteins could serve as diffusible mediators in a low flow environment such as
the inflamed tissue. The identification of the required platelet response(s) will be a critical
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first step for a better understanding of how these cells safeguard vascular integrity at sites of
inflammation.
In humans, marked thrombocytopenia, such as observed in Idiopathic Thrombocytopenia
Purpura, does not necessarily lead to bleeding 122. However, hemorrhage is frequent in
patients suffering from Wiskott-Aldrich syndrome, a clinical complication characterized by
marked thrombocytopenia, recurrent infections, and an elevated risk for development of
autoimmune disease 123, 124. Thus, it seems likely that both thrombocytopenia and an
additional “trigger” such as inflammation are required to compromise the integrity of the
vasculature in humans. Moreover, patients deficient in GPVI expression and/or function
often present with ecchymoses, i.e. hematomas that are not caused by trauma 125, 10,
suggesting that humans also depend on platelet ITAM signaling for maintenance of vascular
integrity. To date, no patients with defects in CLEC-2 expression/function have been
described.
Conclusions
Platelet-mediated hemostasis has classically been defined in the context of plug formation at
sites of vessel injury and high fluid shear forces. Platelet integrins and G protein-coupled
receptor activation pathways are essential in this context and form the foundation of modern
anti-platelet therapies. In contrast, studies of ITAM-coupled platelet receptors are revealing
new aspects of hemostasis that extend far beyond classic arterial injury responses. These
include inflammatory and lympho-venous hemostasis, processes that depend on platelet
ITAM signaling and platelet responses that have yet to be defined. In addition to our deficit
in understanding of the basic mechanisms by which platelets safeguard vascular integrity,
we lack information on when these inflammatory and LV hemostatic responses are most
utilized in normal physiology and under pathophysiologic conditions? Without this
knowledge, it will be difficult to predict which patients taking anti-platelet agents are at an
increased risk of inflammatory or LV hemorrhage. Future studies addressing these questions
have the potential to reveal new roles for platelets in common diseases, and new effects -
both good and bad - of anti-platelet therapies in patients.
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Btk Bruton’s tyrosine kinase
CHF congestive heart failure
CLEC2 C-type lectin 2
DAG diacylglycerol
DIC disseminated intravascular coagulation
EC endothelial cell
ECM extracellular matrix
FcRγIIA Fc receptor γ II A
Gad Grb2 adaptor downstream of Shc
GPIbα glycoprotein Ib subunitα
GPCR G protein-coupled receptors
GPVI glycoprotein VI
Grb2 growth factor receptor bound protein-2
HIT heparin-induced thrombocytopenia and thrombosis
hIL4R human interleukin 4 receptor
ITAM immunoreceptor tyrosine-based activation motif
ITT immune-mediated thrombocytopenia and thrombosis
IL-1 interleukin 1
LAT linker for activation of T cells
LEC lymphatic endothelial cells
LV lympho-venous
PAR protease activated receptor
PDPN podoplanin
PI3K phosphatidyl inositol-3 kinase
PKC protein kinase C
PLC β/γ phospholipase C β/γ
PROX1 prospero homeobox protein 1
SLP76 SH2 containing leukocyte protein of 76 kDa
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Figure 1. Platelet-dependent hemostasis after vascular injury and at sites of inflammation
Schematic representation of important molecular mechanisms regulating platelet-dependent hemostasis. At sites of vascular
injury, platelet activation and adhesion is strongly dependent on soluble agonists and their respective G protein-coupled
receptors (GPCRs) expressed on the platelet surface. Engagement of GPCRs leads to the rapid activation of phospholipase
(PL)Cβ2 and PI3 kinase, events that are critical for the activation of the small GTPase Rap1, affinity regulation in platelet
integrins, and platelet aggregate formation. The contribution of immunoreceptor tyrosine-based activation motif (ITAM)-
coupled receptors to platelet activation at sites of vascular injury is weak when compared to GPCRs. In contrast, hemostasis at
sites of inflammation depends primarily on platelet ITAM signaling and is independent of major platelet adhesion receptors.
These findings suggest a model where platelets get activated under low/no flow conditions in the extravascular space, leading to
the release of soluble factors that secure vascular integrity. Both the signaling response downstream of PLCγ2 and the platelet-
derived mediator(s) critical for vascular integrity in inflammation are currently unknown.
PAR: protease activated receptor; TxA2: thromboxane A2; TP: TxA2 receptor; FcRγ: Fc receptor γ-chain; CLEC2: C-type
lectin 2; PDPN: podoplanin; PI3K: PI3 kinase; PLC: phospholipase C; ECM: extracellular matrix
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